Lindus Health Raises $55M to Revolutionize Clinical Trials

Lindus Health Secures $55 Million to Disrupt Clinical Trials

A London-based startup, established four years ago and supported by Peter Thiel, has successfully closed a $55 million Series B funding round. This investment will be utilized to address inefficiencies within the clinical trial sector.

This announcement coincides with the increasing impact of artificial intelligence on the processes of drug discovery and development. Consequently, there's a growing need for a more efficient clinical trial system to accelerate the delivery of novel medications.

The Lindus Health Platform: A New Approach

Lindus Health has developed a comprehensive platform designed to manage all stages of clinical trial execution. Automation is a key component of their system, leading the company to position itself as the “anti-CRO” – a departure from traditional models.

For those unfamiliar, a CRO, or contract research organization, provides external research services to pharmaceutical, biotechnology, and medical device companies. This allows these companies to concentrate on their primary drug development activities.

Market Growth and Opportunity

The CRO market was valued at $82 billion in the previous year. Projections indicate substantial growth, with an anticipated value of $130 billion by the decade's end.

• The platform streamlines the entire clinical trial workflow.
• Lindus Health aims to accelerate the process of bringing new medicines to patients.
• The company challenges the conventional CRO model through automation.

Lindus Health’s funding reflects the increasing demand for innovative solutions within the clinical trial landscape. The company is poised to capitalize on the expanding market and the transformative potential of AI in pharmaceutical research.

Challenges and Progress in Clinical Trials

Clinical trials, though differing in scale and complexity, generally proceed through multiple phases. These phases encompass trial design, protocol development, and the preparation of necessary regulatory documentation. Subsequently, the infrastructure for trial execution must be established, patients recruited, and data meticulously collected.

This entire process can extend over several years. Therefore, any innovation capable of accelerating the timeline is highly valuable, particularly when a potentially life-saving treatment is involved.

Streamlining Trial Processes with Machine Learning

Lindus Health utilizes machine learning to optimize various aspects of this process. A key application is in the design of the initial trial protocol – a detailed and often time-consuming undertaking.

To address this, Lindus has developed a protocol generation tool. This tool is trained on a comprehensive dataset of historical trial information, enabling it to produce a preliminary draft efficiently.

A Comprehensive Clinical Trial Solution

While the company’s software is central to its offerings, co-founder Meri Beckwith emphasizes that Lindus provides a complete, end-to-end clinical trial service. This includes the provision of qualified personnel to manage and execute the trials.

“We have directly enrolled and treated over 35,000 patients to date,” Beckwith stated in a recent interview with TechCrunch. “Our team comprises medical professionals, physicians, technologists, and regulatory experts who oversee data, clinical operations, and compliance.”

Areas of Focus and Company History

Established in 2021, Lindus Health has conducted clinical trials across both Europe and the United States. Their work centers on a range of conditions, including asthma, acne, chronic fatigue syndrome, diabetes, hypertension, weight management, and social anxiety.

These trials involve evaluating both pharmaceutical drugs and innovative medical devices.

Addressing Neglected Conditions

Beckwith highlighted a common thread among the conditions Lindus focuses on. “Many of these are complex and widespread ailments affecting a significant portion of the population,” she explained. “Unfortunately, they have often been overlooked by the broader industry.”

Lindus aims to address this gap by providing efficient and comprehensive clinical trial solutions for these often-neglected health challenges.

Drug Discovery

The increasing prominence of artificial intelligence is generating numerous ethical and legal challenges. However, its potential applications within healthcare, specifically in the field of drug discovery, are generating considerable enthusiasm.

Numerous startups have secured substantial funding to leverage AI in the drug discovery process, with Google’s DeepMind being a central player. DeepMind CEO Demis Hassabis and John Jumper were awarded the Nobel Prize in Chemistry in October for their development of AlphaFold. This deep learning model predicts the three-dimensional structure of proteins – vital data for disease research and the identification of new drug possibilities.

AlphaFold's Impact

Hassabis suggests that advancements like these could lead to cures for all human diseases within the next ten years. Initial results are encouraging, but the true value of this technology will be determined by the outcomes of clinical trials. Similar to the drug discovery sector, many startups are attracting venture capital to modernize the traditionally slow clinical trial industry.

This prompts a key inquiry: is the current excitement surrounding AI-driven drug discovery increasing the need for advanced clinical trial technologies?

Beckwith believes a connection exists between these trends.

“Essentially, these AI drug discovery firms won’t realize their full potential unless we address the limitations within clinical trials,” he explained. “These companies generate targets and formulate hypotheses regarding drugs or specific patient groups, but these still require validation through testing.”

Challenges in Biotech

The practice of rapid testing, iteration, and code deployment is commonplace for software companies. However, the biotech industry, even with software at its core, has struggled to embrace a similar “move fast and break things” approach.

This caution is understandable, given the significant difference between creating an online marketplace and developing pharmaceuticals that save lives. Nevertheless, Beckwith argues that improvements can be achieved through more streamlined clinical trial infrastructure.

“Our company’s goal is to assist biotech firms in testing and iterating more quickly, and with enhanced patient safety,” he stated.

• AI in Drug Discovery: Leveraging artificial intelligence to accelerate the identification of potential drug candidates.
• AlphaFold: A deep learning model predicting protein structures, crucial for disease research.
• Clinical Trial Bottlenecks: The need for more efficient and rapid clinical trials to validate AI-generated hypotheses.

Lindus Health Secures $55 Million in Series B Funding

Lindus Health had formerly secured approximately $25 million through equity and grant funding, notably including an $18 million Series A investment in 2023. This previous funding round featured contributions from Creandum, an investor in Spotify, and Peter Thiel, a well-known billionaire entrepreneur.

The company is now poised to significantly accelerate its growth plans following a new investment of $55 million. This includes a current relocation of its global headquarters from the United Kingdom to the United States.

Further investment will be directed towards strengthening Lindus’s commercial team and broadening its capabilities to encompass more intricate clinical trial methodologies.

Expansion efforts will also focus on enhancing integrations with existing third-party systems, such as electronic medical records.

AI Integration Plans

Like many forward-thinking organizations in 2025, Lindus Health is actively investigating the potential of artificial intelligence (AI) throughout its operations.

Specifically, the company is exploring methods for real-time analysis of clinical trial data using AI technologies.

“We are only beginning to understand the full potential of AI,” stated Beckwith.

Investment Details

Balderton Capital spearheaded Lindus Health’s Series B funding round.

Additional support was provided by Creandum, Firstminute, Seedcamp, and Visionaries Club.